PMID

Data

Article Title

Organization

Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity.

University of Bath

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.

Health & Science University

Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment.

Shandong First Medical University and Shandong Academy of Medical Sciences

Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models.

Merck

Fused-azepinones: Emerging scaffolds of medicinal importance.

National Institute of Pharmaceutical Education and Research (NIPER)

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-

Astrazeneca

Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives.

University of Bologna

Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules.

University of Perugia

Potent 2,3-dihydrophthalazine-1,4-dione derivatives as dual inhibitors for mono-ADP-ribosyltransferases PARP10 and PARP15.

University of Perugia

Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II.

Symeres

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.

TBA

Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.

Lupin

Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.

University of Oslo

Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.

Nerviano Medical Sciences

Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.

Merck Healthcare

Rational Design of Cell-Active Inhibitors of PARP10.

Oregon Health and Science University

Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.

Astrazeneca

4-(Phenoxy) and 4-(benzyloxy)benzamides as potent and selective inhibitors of mono-ADP-ribosyltransferase PARP10/ARTD10.

University of Oulu

Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.

Leibniz-Forschungsinstitut F�R Molekulare Pharmakologie (Fmp)

Chemical compounds

Astrazeneca

Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors

Beigene